CD66acde Antibody, anti-human, REAfinity™
Synonyms: BGP-1, CEACAM5, CEACAM3, CEACAM6, BGP-1, CGM1, NCA, CEA, CEACAM1
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
4 Citations
Clone:
REA428 | B1.1/CD66
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD66acde Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright FITC
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-126-512, 130-126-549
Description:
Human peripheral blood cells after erythrocyte lysis were stained with CD66acde antibodies or with the corresponding REA Control (S) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. Granulocytes cells were pregated for the analysis based on scatter signals. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-126-512, 130-126-549
Testing grade:
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-126-512, 130-126-549
Testing grade:
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-126-512, 130-126-549
Testing grade:
Extended validation for CD66acde Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA428
B1.1/CD66
high
REA414
partial

Cells were incubated with an excess of purified unconjugated CD66acde (REA428) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD66acde. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD66acde antibodies and with a suitable counterstaining. As a control, CD66acde antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD66 acde shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD66acde (REA428). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD66acde Antibody, anti-human, REAfinity™
Overview

Clone REA428 recognizes an epitope shared by the human CD66a, c, d, and e antigens, which are also known as the human carcinoembryonic antigen (CEA) family. The CEA family has 7 genes belonging to the CEACAM subgroup. These subgroup members are mainly associated with the cell membrane and show a complex expression pattern in normal and cancerous tissues. CD66a (CEACAM1) is an adhesion molecule that is involved in many immune responses associated with infection, inflammation, and cancer. It interacts homophilically with CD66a and heterophilically with CD66e (CEACAM5), but not with other CEACAM proteins. CD66a is expressed on a variety of cells, e.g., some epithelial cells, melanoma, and activated lymphocytes. Within the hematopoietic system, CD66c (CEACAM6) expression is limited to granulocytes and its precursors, where it serves homotypic and heterotypic adhesion and Ca2+ mediated signaling. It is markedly upregulated from intracellular stores after activatio and is also found in epithelia of various organs. CD66c overexpression is found in a wide variety of epithelial cancer types such as lung, breast, colorectal, and hepatocellular carcinomas. CD66d (CEACAM3) is a major granulocyte receptor mediating recognition and efficient opsonin-independent phagocytosis of CEACAM-binding microorganisms, thus playing an important role in the clearance of pathogens by the innate immune system. CD66e (CEACAM5) plays a role in cell adhesion and in intracellular signaling. It is known to be overexpressed in a majority of carcinomas, including those of the gastrointestinal tract, the respiratory and genitourinary systems, and breast cancer.

Additional information: Clone REA428 displays negligible binding to Fc receptors.

Alternative names

BGP-1, CEACAM5, CEACAM3, CEACAM6, BGP-1, CGM1, NCA, CEA, CEACAM1

Detailed product information

Technical specifications

Clone
REA428
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD66acde
Molecular mass of antigen [kDa]
45, average of subunits
Distribution of antigen
epithelial cells, granulocytes, lymphocytes, melanoma
Entrez Gene ID
RRID
AB_2905096, AB_2905095, AB_2658978, AB_2658981, AB_2658976, AB_2658973, AB_2658977, AB_2658972, AB_2658970, AB_2889616, AB_2857753, AB_2658979, AB_2658980, AB_2658971, AB_2889617, AB_2857765

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD66acde Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support